In patients with neuromyelitis optica spectrum disorder, transition from rituximab to inebilizumab was linked to suppression of attacks over a mean 19 months of treatment, according to research published in Frontiers in Neurology.
“Although we have three new FDA approved therapies to prevent relapses, many people with [neuromyelitis optica spectrum disorder] remain on off-label rituximab infusions which were widely used prior to the approved treatments,” Michael Levy, MD, PhD, study co-author and an associate professor of neurology at Harvard Medical School, told Healio in an